80 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
product candidates cause serious adverse events or undesirable side effects, including injury and death, or have other properties that could delay … CAR- T cell therapy with programmed cell death protein 1 (“PD-1”) removed from the CAR-T cell surface by a genome-edited knockout of the PDCD1 gene. We
DEFA14A
CRBU
Caribou Biosciences Inc
25 Apr 24
Additional proxy soliciting materials
4:04pm
the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death
424B5
yjfyd ycgqtcewbc7x
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
qjba1py wp4g5g
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-99.2
1o9gyop8
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
8-K
kbpy0unnk fuftph9e
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
ARS
z42g3c9x7lmq2
28 Apr 23
Annual report to shareholders
12:00am
8-K/A
45c4o8r3 g8r6ub
22 Sep 22
Submission of Matters to a Vote of Security Holders
6:42pm
8-K
k7zzcywdh s4x
22 Sep 22
Submission of Matters to a Vote of Security Holders
4:05pm
DEF 14A
3zyh35fn0
11 Aug 22
Definitive proxy
4:04pm